丹参联合抗栓治疗急性冠脉综合征患者的安全性和有效性

Safety and efficacy of Danshen Injection combined with antithrombotic therapy in patients with acute coronary syndrome

目的观察丹参联合抗栓治疗急性冠脉综合征(ACS)对患者不良事件和凝血功能的影响,进而评价联合治疗急性冠脉综合征的安全性和有效性。方法将63例急性冠脉综合征患者随机分成治疗组35例、对照组28例,对照组采用西医强化抗栓,治疗组在西医治疗的基础上加用丹参注射液。观察治疗后2组的不良事件(再发心血管事件、出血事件以及其他不良反应)和对凝血功能(血小板计数、活化部分凝血活酶时间)的影响。结果2组不良事件发生情况无明显差异。2组血小板计数治疗后较本组治疗前均有所减少,2组治疗前后差值比较无显著性差异。2组活化部分凝血活酶时间治疗后较本组治疗前均有所提高,治疗组较对照组提高显著,P<0.05。结论丹参联合抗栓治疗能够有效延长活化部分凝血活酶时间而不增加出血并发症,达到较好的抗栓效果。

Objective To observe the influences of Danshen Injection combined with antithrombotic therapy on the adverse events and coagulation function in the patients with acute coronary syndrome （ACS） in order to review the safety and efficacy of the therapy in the treatment of ACS. Method The patients with ACS （n=63） were randomly divided into the treatment group （n=35） and control group （n=28）. The control group was given strengthening antithrombotic therapy of Western medicine, and the treatment group was given Danshen Injection based on the antithrombotic therapy of Western medicine. The adverse events （recurrent cardiovascular events, bleeding events and other adverse reactions） and changes of coagulation function [platelet count （PLT） and activated partial thromboplastin time （APTT）] were observed before and after the treatment. Result The occurrence of adverse events was not different between two groups. PLT decreased after the treatment in two groups respectively, but there was no difference in the comparison in each group before and after the treatment. APTT increased after the treatment in two groups respectively than that before the treatment and increased more significantly in the treatment group （P〈0.05）. Conclusion Danshen Injection combined with antithrombotic therapy may prolong effectively AprFr but not improve the occurrence of hemorrhage complication, with a better antithrombotic effect.